BioCryst Pharmaceuticals (BCRX) reported Friday preliminary Q4 revenue of $130.8 million, up 40% year over year.
Analysts polled by FactSet expected $128.6 million.
The company said it expects full-year 2025 revenue between $540 million and $560 million. Analysts polled by FactSet expect $536.4 million.
Shares of the company fell 4.5% in recent trading.
Price: 7.69, Change: -0.36, Percent Change: -4.47
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。